FDA says on June 30th it sent a letter to Keryx Biopharma (Nasdaq: KERX) alleging the company promoted its unapproved and investigational drug on the company's website.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.